ArticleJournal of medicinal chemistry2026
Development of PROTACs Targeting the Moonlighting Enzyme Nicotinamide Phosphoribosyltransferase (NAMPT) for Breast Cancer Therapy.
Ubaldina Galli, Marianna Moro, Federica Carolina Balestrero, Giorgia Colombo, Marco Koten, Benedetta Roncaglio, Armando A Genazzani, Silvio Aprile, Alberto Massarotti, Giuseppe Orsomando and 2 more
Abstract read
In one paragraphArticle in Journal of medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
12 authors.
Ubaldina GalliDepartment of Pharmaceutical Sciences, Università degli Studi del Piemonte Orientale, Largo Donegani 2, 28100 Novara, Italy.ORCID 0000-0003-1126-0142 Marianna MoroDepartment of Pharmaceutical Sciences, Università degli Studi del Piemonte Orientale, Largo Donegani 2, 28100 Novara, Italy.
Federica Carolina BalestreroDepartment of Pharmaceutical Sciences, Università degli Studi del Piemonte Orientale, Largo Donegani 2, 28100 Novara, Italy.
Giorgia ColomboDepartment of Pharmaceutical Sciences, Università degli Studi del Piemonte Orientale, Largo Donegani 2, 28100 Novara, Italy.
Marco KotenDepartment of Pharmaceutical Sciences, Università degli Studi del Piemonte Orientale, Largo Donegani 2, 28100 Novara, Italy.
Benedetta RoncaglioDepartment of Pharmaceutical Sciences, Università degli Studi del Piemonte Orientale, Largo Donegani 2, 28100 Novara, Italy.
Armando A GenazzaniDepartment of Pharmaceutical Sciences, Università degli Studi del Piemonte Orientale, Largo Donegani 2, 28100 Novara, Italy.
Silvio AprileDepartment of Pharmaceutical Sciences, Università degli Studi del Piemonte Orientale, Largo Donegani 2, 28100 Novara, Italy.ORCID 0000-0003-4804-9543 Alberto MassarottiDepartment of Pharmaceutical Sciences, Università degli Studi del Piemonte Orientale, Largo Donegani 2, 28100 Novara, Italy.ORCID 0000-0001-9306-8845 Giuseppe OrsomandoDepartment of Clinical Sciences (DISCO), Section of Biochemistry, Polytechnic University of Marche, Via Ranieri 67, 60131 Ancona, Italy.
Tracey PiraliDepartment of Pharmaceutical Sciences, Università degli Studi del Piemonte Orientale, Largo Donegani 2, 28100 Novara, Italy.ORCID 0000-0003-3936-4787 Ambra A GrollaDepartment of Pharmaceutical Sciences, Università degli Studi del Piemonte Orientale, Largo Donegani 2, 28100 Novara, Italy.
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
PROTACs (proteolysis-targeting chimeras) enable selective protein degradation through the ubiquitin-proteasome system and offer opportunities to target moonlighting proteins with nonenzymatic functions. We report the design, synthesis, and biological evaluation of NAMPT-directed PROTACs derived from our previously described inhibitor MV78 (
Indexed as
Antineoplastic AgentsBreast NeoplasmsCytokinesEnzyme InhibitorsNicotinamide PhosphoribosyltransferaseAnimalsCell Line, TumorCell ProliferationFemaleHumansProteolysisProteolysis Targeting ChimeraStructure-Activity RelationshipTriazolesAntineoplastic AgentsCytokinesEnzyme InhibitorsNicotinamide Phosphoribosyltransferasenicotinamide phosphoribosyltransferase, humanProteolysis Targeting ChimeraTriazoles
Identifiers
PMID41712316
PMCPMC12990041
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390